[1] Roilides E, Lyman CA, Filioti J, et al. Amphotericin B formulations exert additive antifungal activity in combination with pulmonary alveolar macrophages and polymorphonuclear leukocytes against Aspergillus fumigatus[J]. Antimicrob Agents Chemother, 2002, 46(6):1974-1976.
[2] Ries F, Alflen A, Aranda Lopez P, et al. Antifungal drugs influence neutrophil effector functions[J]. Antimicrob Agents Chemother, 2019, 63(6):e02409-18.
[3] Simitsopoulou M, Roilides E, Georgiadou E, et al. Differential transcriptional profiles induced by amphotericin B formulations on human monocytes during response to hyphae of Aspergillus fumigatus[J]. Med Mycol. 2011, 49(2):176-185.
[4] Ben-Ami R, Lewis RE, Kontoyiannis DP. Immunocompromised hosts:immunopharmacology of modern antifungals[J]. Clin Infect Dis, 2008, 47(2):226-235.
[5] Mesa-Arango AC, Trevijano-Contador N, Roman E, et al. The production of reactive oxygen species is a universal action mechanism of amphotericin B against pathogenic yeasts and contributes to the fungicidal effect of this drug[J]. Antimicrob Agents Chemother, 2014, 58(11):6627-6638.
[6] Mesa-Arango AC, Scorzoni L, Zaragoza O. It only takes one to do many jobs:amphotericin B as antifungal and immunomodulatory drug[J]. Front Microbiol, 2012, 3:286.
[7] Razonable RR, Henault M, Lee LN, et al. Secretion of proinflammatory cytokines and chemokines during amphotericin B exposure is mediated by coactivation of toll-like receptors 1 and 2[J]. Antimicrob Agents Chemother, 2005, 49(4):1617-1621.
[8] Hedges JF, Mitchell AM, Jones K, et al. Amphotericin B stimulates gammadelta T and NK cells, and enhances protection from Salmonella infection[J]. Innate Immun, 2015, 21(6):598-608.
[9] Kim N, Choi JW, Park HR, et al. Amphotericin B, an anti-fungal medication, directly increases the cytotoxicity of NK cells[J]. Int J Mol Sci, 2017, 18(6):1262.
[10] Sarthou P, Primi D, Cazenave PA. B cell triggering properties of a nontoxic derivative of amphotericin B[J]. J Immunol, 1986, 137(7):2156-2161.
[11] Bellocchio S, Gaziano R, Bozza S, et al. Liposomal amphotericin B activates antifungal resistance with reduced toxicity by diverting Toll-like receptor signalling from TLR-2 to TLR-4[J]. J Antimicrob Chemother, 2005, 55(2):214-22.
[12] Okwor I, Uzonna JE. Immunotherapy as a strategy for treatment of leishmaniasis:a review of the literature[J]. Immunotherapy, 2009, 1(5):765-776.
[13] Lewis RE, Chamilos G, Prince RA, et al. Pretreatment with empty liposomes attenuates the immunopathology of invasive pulmonary aspergillosis in corticosteroid-immunosuppressed mice[J]. Antimicrob Agents Chemother, 2007, 51(3):1078-1081.
[14] Arning M, Kliche KO, Heer-Sonderhoff AH, et al. Infusion-related toxicity of three different amphotericin B formulations and its relation to cytokine plasma levels[J]. Mycoses, 1995, 38(11-12):459-465.
[15] Simitsopoulou M, Roilides E, Dotis J, et al. Differential expression of cytokines and chemokines in human monocytes induced by lipid formulations of amphotericin B[J]. Antimicrob Agents Chemother, 2005, 49(4):1397-1403.
[16] Ha KC, White TC. Effects of azole antifungal drugs on the transition from yeast cells to hyphae in susceptible and resistant isolates of the pathogenic yeast Candida albicans[J]. Antimicrob Agents Chemother, 1999, 43(4):763-768.
[17] Simitsopoulou M, Roilides E, Paliogianni F, et al. Immunomodulatory effects of voriconazole on monocytes challenged with Aspergillus fumigatus:differential role of Toll-like receptors[J]. Antimicrob Agents Chemother, 2008, 52(9):3301-3306.
[18] Simitsopoulou M, Roilides E, Likartsis C, et al. Expression of immunomodulatory genes in human monocytes induced by voriconazole in the presence of Aspergillus fumigatus[J]. Antimicrob Agents Chemother, 2007, 51(3):1048-1054.
[19] Choi JH, Kwon EY, Park CM, et al. Immunomodulatory effects of antifungal agents on the response of human monocytic cells to Aspergillus fumigatus conidia[J]. Med Mycol, 2010, 48(5):704-709.
[20] Farowski F, Cornely OA, Hartmann P. High intracellular concentrations of posaconazole do not impact on functional capacities of human polymorphonuclear neutrophils and monocyte-derived macrophages in vitro[J]. Antimicrob Agents Chemother, 2016, 60(6):3533-3539.
[21] Decker C, Wurster S, Lazariotou M, et al. Analysis of the in vitro activity of human neutrophils against Aspergillus fumigatus in presence of antifungal and immunosuppressive agents[J]. Med Mycol, 2018, 56(4):514-519.
[22] Kanda N, Enomoto U, Watanabe S. Anti-mycotics suppress interleukin-4 and interleukin-5 production in anti-CD3 plus anti-CD28-stimulated T cells from patients with atopic dermatitis[J]. J Invest Dermatol, 2001, 117(6):1635-1646.
[23] Kennedy JL, Steinke JW, Liu L, et al. Failure of itraconazole to prevent T-helper type 2 cell immune deviation:Implications for chronic rhinosinusitis[J]. Am J Rhinol Allergy, 2016, 30(6):379-384.
[24] Cenci E, Mencacci A, Del Sero G, et al. Induction of protective Th1 responses to Candida albicans by antifungal therapy alone or in combination with an interleukin-4 antagonist[J]. J Infect Dis, 1997, 176(1):217-226.
[25] Liebel F, Lyte P, Garay M, et al. Anti-inflammatory and anti-itch activity of sertaconazole nitrate[J]. Arch Dermatol Res, 2006, 298(4):191-199.
[26] Sur R, Babad JM, Garay M, et al. Anti-inflammatory activity of sertaconazole nitrate is mediated via activation of a p38-COX-2-PGE2 pathway[J]. J Invest Dermatol, 2008, 128(2):336-344.
[27] Nakamura A, Uratsuji H, Yamada Y, et al. Anti-inflammatory effect of lanoconazole on 12-O-tetradecanoylphorbol-13-acetate- and 2,4,6-trinitrophenyl chloride-induced skin inflammation in mice[J]. Mycoses, 2020, 63(2):189-196.
[28] Rosowski EE, He J, Huisken J, et al. Efficacy of voriconazole against Aspergillus fumigatus infection depends on host immune function[J]. Antimicrob Agents Chemother, 2020, 64(2):e00917-19
[29] Khandpur S, Sugandhan S, Sharma VK. Pulsed itraconazole therapy in eruptive lichen planus[J]. J Eur Acad Dermatol Venereol, 2009, 23(1):98-101.
[30] Brouwers KJ, Vis R, Tupker RA. Itraconazole as a continuous treatment for atopic dermatitis? A case report[J]. J Eur Acad Dermatol Venereol, 2016, 30(5):873-874.
[31] Abbas Z, Ghodsi SZ, Abedeni R. Effect of itraconazole on the quality of life in patients with moderate to severe seborrheic dermatitis:a randomized, placebo-controlled trial[J]. Dermatol Pract Concept, 2016, 6(3):11-16.
[32] van Asbeck EC, Hoepelman AI, Scharringa J, et al. The echinocandin caspofungin impairs the innate immune mechanism against Candida parapsilosis[J]. Int J Antimicrob Agents, 2009, 33(1):21-26.
[33] Kinoshita K, Iwasaki H, Uzui H, et al. Candin family antifungal agent micafungin (FK463) modulates the inflammatory cytokine production stimulated by lipopolysaccharide in THP-1 cells[J]. Transl Res, 2006, 148(4):207-213.
[34] Moretti S, Bozza S, Massi-Benedetti C, et al. An immunomodulatory activity of micafungin in preclinical aspergillosis[J]. J Antimicrob Chemother, 2014, 69(4):1065-1074.
[35] Tullio V, Mandras N, Scalas D, et al. Synergy of caspofungin with human polymorphonuclear granulocytes for killing Candida albicans[J]. Antimicrob Agents Chemother, 2010, 54(9):3964-3966.
[36] Chiller T, Farrokhshad K, Brummer E, et al. The interaction of human monocytes, monocyte-derived macrophages, and polymorphonuclear neutrophils with caspofungin (MK-0991), an echinocandin, for antifungal activity against Aspergillus fumigatus[J]. Diagn Microbiol Infect Dis, 2001, 39(2):99-103.
[37] Lamaris GA, Lewis RE, Chamilos G, et al. Caspofungin-mediated beta-glucan unmasking and enhancement of human polymorphonuclear neutrophil activity against Aspergillus and non-Aspergillus hyphae[J]. J Infect Dis, 2008, 198(2):186-192.
[38] Moretti S, Bozza S, D'Angelo C, et al. Role of innate immune receptors in paradoxical caspofungin activity in vivo in preclinical aspergillosis[J]. Antimicrob Agents Chemother, 2012, 56(8):4268-4276.
[39] Spellberg B, Schwartz J, Fu Y, et al. Comparison of antifungal treatments for murine fusariosis[J]. J Antimicrob Chemother, 2006, 58(5):973-979.
[40] Subissi A, Monti D, Togni G, et al. Ciclopirox:recent nonclinical and clinical data relevant to its use as a topical antimycotic agent[J]. Drugs, 2010, 70(16):2133-2152.